Publications by authors named "Meltem Selam"
Article Synopsis
- The study looked at how well a drug called Atezolizumab (ATZ) worked for patients with a tough type of cancer that didn't respond to earlier treatment.*
- Researchers checked the health data of 113 patients to find out which factors might affect how long they lived after taking ATZ.*
- Important factors that seemed to be linked to shorter survival included having liver metastases, poor overall health, and low hemoglobin levels.*
Background: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinum-resistant urothelial carcinoma.
Objective: To compare the real-life experience and data of clinical trials on ATZ treatment in metastatic urothelial carcinoma.
Design, Setting, And Participants: Patients with urothelial cancer treated with ATZ after progression on first-line chemotherapy from an expanded access program were retrospectively studied.
Our patient was a 35-year-old woman, who had undergone right radically modified mastectomy and axillary-lymph-nodes dissection in June 2004. The stage of the patient was T2N0M0. She was treated with six cycles of FAC (5-fluorouracil, doxorubicin, cyclofosfamid), tamoxifen after chemotherapy.
View Article and Find Full Text PDFObjective: To evaluate the clinicopathological prognostic factors and outcome of chemotherapy in ovarian carcinosarcomas.
Methods: We reviewed the records of 26 patients treated from 1990 to 2006 at the Oncology Institute of Istanbul University. Clinical data including demographics, stage, surgery, chemotherapy, and survival were collected from patients' charts.
Background: Angiogenesis is regulated by a balance of both angiogenic inducers and inhibitors. This study was designed to evaluate the effect of both maximum-tolerated doses (MTD) and low-dose metronomic chemotherapy (LDM) on serum vascular endothelial growth factor (VEGF), thrombospondin-1 (TSP1) and VEGFR1 concentrations in patients with advanced nonsmall cell lung cancer.
Patients And Methods: Forty consecutive patients with advanced stage nonsmall cell lung cancer were included in this prospective study.